tipifarnib has been researched along with Acute Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, D; Belly, RT; Karp, JE; Lancet, JE; Raponi, M; Wang, Y | 1 |
| Zhang, GS | 1 |
| Feldman, EJ | 1 |
| Grever, MR | 1 |
| Sekeres, MA | 1 |
| De Porre, P; Fenaux, P; Harousseau, JL; Huguet, F; Lancet, JE; Lowenberg, B; Rackoff, W; Reiffers, J; Stone, R; Thomas, X; Zhang, S | 1 |
3 review(s) available for tipifarnib and Acute Disease
| Article | Year |
|---|---|
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Acute Disease; Aged; Alkyl and Aryl Transferases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Remission Induction; Signal Transduction; Treatment Outcome | 2005 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Thionucleotides | 2003 |
Non-transplant therapy for older adults with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aminoglycosides; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytarabine; Cytogenetic Analysis; Gemtuzumab; Humans; Leukemia, Myeloid; Quinolones | 2006 |
1 trial(s) available for tipifarnib and Acute Disease
| Article | Year |
|---|---|
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Bone Marrow Cells; Farnesyltranstransferase; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Quinolones; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
3 other study(ies) available for tipifarnib and Acute Disease
| Article | Year |
|---|---|
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
Topics: Acute Disease; Alkyl and Aryl Transferases; Apoptosis; Cell Growth Processes; Farnesyltranstransferase; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Quinolones | 2004 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Molecule of the month. Tipifarnib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Myeloid; Quinolones | 2005 |